Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a mar…
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a mar…
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment H1 headwinds in Specialty Ingredients (…
Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lo…
. • Outperformance in Pharma & Biotech in H1 2018 in sales, with margins up 270 bps, was combined with strong positi…